- NOX66 + low-dose carboplatin in late-stage cancers
- Disease progression blocked in the majority of patients (12/14) after 3 months
6 March 2018, Paris: Noxopharm (ASX:NOX) today presented an update on its Phase 1b clinical study known as CEP-1 to the 2018 ESMO International Congress on Targeted Anticancer Therapies in Paris.
CEP-1 is being conducted at clinics in Georgia, including FDA-inspected sites. It involves patients with late-stage cancers of the lung, breast, ovary and prostate following disease progression after multiple courses of chemotherapy and who have no remaining standard treatment options. The study is fully recruited with the last patient due to complete treatment in April 2018.
For further information please download PDF attached:
Download this document
